Medicago successfully produces plant-based Rotavirus VLP vaccine candidate
See on Scoop.it – Virology and Bioinformatics from Virology.ca
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago’s plant-based manufacturing platform.
Medicago also announced today that an international patent application under the Patent Cooperation Treaty (PCT) that broadly covers plant-produced Rotavirus VLPs has been filed.
Ed Rybicki‘s insight:
Going green – how sensible! B-)
See on www.marketwatch.com
